Stock Analysis
IM Cannabis Third Quarter 2023 Earnings: CA$0.16 loss per share (vs CA$0.59 loss in 3Q 2022)
IM Cannabis (CSE:IMCC) Third Quarter 2023 Results
Key Financial Results
- Revenue: CA$12.4m (down 13% from 3Q 2022).
- Net loss: CA$2.15m (loss narrowed by 48% from 3Q 2022).
- CA$0.16 loss per share (improved from CA$0.59 loss in 3Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
IM Cannabis Earnings Insights
Looking ahead, revenue is forecast to grow 7.9% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada.
Performance of the Canadian Pharmaceuticals industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
We should say that we've discovered 5 warning signs for IM Cannabis (3 are concerning!) that you should be aware of before investing here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CNSX:IMCC
IM Cannabis
Engages in breeding, growing, and supply of medical cannabis products in Israel and Germany.